References
- 1. Turner PR, Denny WA. The mutagenic properties of DNA minor-groove binding ligands. Mutat Res 1996;355:141-69. PMID: 8781582
- 2. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Therap 2009;121:29-40. doi: 10.1016/j. pharmthera.2008.09.005
- 3. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-77. doi: 10.1021/np068054v
- 4. Hamilton PL, Arya DP. Natural product DNA major groove binders. Nat Prod Rep 2012;29:134-43. doi: 10.1039/ c1np00054c
- 5. Dervan PB. Molecular recognition of DNA by small molecules. Bioorg Med Chem 2001;9:2215-35. doi: 10.1016/ S0968-0896(01)00262-0
- 6. Wasselbourg S, Lauber K. Mechanisms of anticancer drug action. In: Los M, Gibson SB, editors. Apoptotic pathways as targets for novel therapies in cancer and other diseases. New York (NY): Springer Science Business Media, Inc.; 2005. p. 31-55.
- 7. Hoti N, Ma J, Tabassum S, Wang Y, Wu M. Triphenyl tin benzimidazolethiol, a novel antitumor agent, induces mitochondrial-mediated apoptosis in human cervical cancer cells via suppression of HPV-18 Encoded E6. J Biochem 2003;134:521-8. PMID: 14607978
- 8. Liu J, Campen A, Huang S, Peng S,Ye X, Palakal M, Dunker KA, Xia Y, Li S. Identifi cation of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profi ling data. BMC Med Genomics 2008;1:39-51. doi: 10.1186/1755-8794-1-39
- 9. Haq I. Thermodynamics of drug-DNA interactions. Arch Biochem Biophys 2002;15:1-15. PMID: 12061796
- 10. Gurova K. New hopes for old drugs: revising DNA-binding small molecules as anticancer agents. Future Oncol 2009;5:1685-704. doi: 10.2217/fon.09.127
- 11. Leal JFM, Martinez-Diez M, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillen-Navarro MJ, Aviles P, Cuevas C, Garcia-Fernandez LF, Galmarini CM. PMO1183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol 2010;161:1099-110. doi: 10.1111/ j.1476-5381.2010.00945.x
- 12. Tidwell RR, Boykin DW. Dicationic DNA minor groove binders as antimicrobial agents. In: Demeunynck M, Bailly C, Wilson WD, editors. DNA and RNA binders: from small molecules to drugs. Vol. 2. Weinheim: Wiley-VCH; 2003. p. 414-60.
- 13. Xi H, Davis E, Ranjan N, Xue L, Hyde-Volpe D, Arya DP. Thermodynamics of nucleic acid “shape readout” by an aminosugar. Biochemistry 2011;50:9088-113. doi: 10.1021/ bi201077h
- 14. Kumar S, Xue L, Arya DP. Neomycin-neomycin dimer: an all-carbohydrate scaffold with high affi nity for AT-rich DNA duplexes. J Am Chem Soc 2011;133:7361-75. doi: 10.1021/ ja108118v
- 15. Zhang X, Zhang SC, Sun D, Hu J, Wali A, Pass H, Fernandez- Madrid F, Harbut MR, Tang N. New insight into the molecular mechanism of the biological effect of DNA minor groove binders. PLoS One. 2011;6:e25822. doi: 10.1371/ journal.pone.0025822
- 16. Avendano C, Menendez CJ. DNA Intercalators and topoisomerase inhibitors. In: Avendano C, Menendez JC, editors. Medicinal chemistry of anticancer drugs. Oxford: Elesevier BV; 2008. p. 199-228.
- 17. Milano A, Perri F, Ciarmiello A, Caponigro F. Targetedtherapy and imaging response: a new paradigm for clinical evaluation? Rev Recent Clin Trials 2011;6:259-65. PMID: 21682675
- 18. Marverti G, Cusumano M, Ligabue A, Di Pietro ML, Vainiglia PA, Ferrari A, Bergomi M, Moruzzi MS, Frassineti C. Studies on the anti-proliferative effects of novel DNAintercalating bipyridyl-thiourea-Pt(II) complexes against cisplatin-sensitive and -resistant human ovarian cancer cells. J Inorg Biochem 2008;102:699-712. PMID: 18082268
- 19. Martinez R, Chacon-Garcia L. The Search of DNAintercalators as antitumoral drugs: what it worked and what did not work. Curr Med Chem 2005;12:127-51. PMID: 15638732
- 20. Raj AS, Heddle JA. Simultaneous detection of chromosomal aberrations and sister-chromatid exchanges: experience with DNA intercalating agents. Mutat Res 1980;78:253-60. PMID: 7432360
- 21. Wilson WR, Harris NM, Ferguson LR. Comparison of the mutagenic and clastogenic activity of amsacrine and other DNA-intercalating drugs in cultured V79 Chinese hamster cells. Cancer Res 1984;44:4420-31. PMID: 6547875
- 22. Palchaudhuri R, Hergenrother PJ. DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotechnol 2007;18:497-503. doi: 10.1016/j.copbio.2007.09.006
- 23. Terakawa T, Miyake H, Muramaki M, Takenaka A, Fujisawa M. Salvage chemotherapy with methotrexate, etoposide and actinomycin D in men with metastatic nonseminomatous germ cell tumors with a choriocarcinoma component: a preliminary report. Int J Urol 2010;17:881-5. doi: 10.1111/ j.1442-2042.2010.02618.x
- 24. Milano A, Apice G, Ferrari E, Fazioli F, de Rosa V, de Luna AS, Laffaioli RV, Caponigro F. New emerging drugs in soft tissue sarcoma. Crit Rev Oncol Hematol 2006;59:74-84. PMID: 16533604
- 25. Schaich M, Illmer T, Aulitzky W, Bodenstein H, Clemens M, Neubauer A, Repp R, Schakel U, Soucek S, Wandt H, Ehninger G. Intensifi ed double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Haematologica 2002;87:808-15. PMID: 12161356
- 26. Fiocchi SC, Selting KA, Rosenberg MP, Kolli P, Lenaz G, Henry C. An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs. J Vet Intern Med 2011;25:897-902. doi: 10.1111/j.1939-1676.2011.0752.x
- 27. He Y, Zhang L, Song C. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modifi ed with PEGylated liposomes. Int J Nanomedicine 2010;5:697-705. PMID: 20957221
- 28. Mocellin S, Rossi CR, Brandes A, Nitti D. Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches. Cancer Treat Rev 2006;32:9-27. PMID: 16338075
- 29. Salas JA, Mendez C. Indolocarbazole antitumour compounds by combinatorial biosynthesis. Curr Opin Chem Biol 2009;13:152-60. doi: 10.1016/j.cbpa.2009.02.003
- 30. Facompre M, Baldeyrou B, Bailly C, Anizon F, Marminon C, Prudhomme M, Colson P, Houssier C. DNA targeting of two new antitumour rebeccamycin derivatives. Eur J Med Chem 2002;37:925-32. PMID: 12660017
- 31. Bailly C, Qu X, Anizon F, Prudhomme M, Ois Riou J, Chaires JB. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Mol Pharmacol 1999;55:377-85. PMID: 9927631
- 32. Sanchez C, Salas AP, Brana AF, Palomino M, Pineda-Lucena A, Carbajo RJ, Mendez C, Moris F, Salas JA. Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated Indolocarbazoles. Chem Commun 2009;27:4118-20. doi: 10.1039/b905068j
- 33. Sanchez C, Zhu L, Brana AF, Salas AP, Rohr J, Mendez C, Salas JA. Combinatorial biosynthesis of antitumor indolocarbazole compounds. PNAS 2005;102:461-6. doi: 10.1073/pnas.0407809102
- 34. Gamage SA, Spicer JA, Finlay GJ, Stewart AJ, Charlton P, Baguley BC, Denny WA. Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. J Med Chem 2001;44:1407-15. PMID: 11311063
- 35. Sappal DS, McClendon KA, Fleming JA, Thoroddsen V, Connolly K, Reimer C, Blackman RK, Bulawa CE, Osheroff N, Charlton P, Rudolph-Owen LA. Biological characterization of MLN944: A potent DNA binding agent. Mol Cancer Ther 2003;3:47-58. PMID: 14749475
- 36. Fujimoto S. Promising antitumor activity of a novel quinoline derivative, TAS-103, against fresh clinical specimens of eight types of tumors measured by fl ow cytometric DNA analysis. Biol Pharm Bull 2007;30:1923-9. PMID: 17917263
- 37. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000;7:39-58. PMID: 10637356
- 38. Baguley BC, Kerr DJ. Anticancer Drug Development. San Diego (CA): Academic Press; 2001.
- 39. Varvaresou A, Iakovou K. Molecular modeling study of intercalation complexes of tricyclic carboxamides with d(CCGGCGCCGG)2 and d(CGCGAATTCGCG)2. J Mol Model 2010;17:2041-50. doi: 10.1007/s00894-010-0891-5
- 40. Williamson NR, Chawrai S, Leeper FJ, Salmond GPC. Prodiginines and their potential utility as proapoptotic anticancer agents. In: Fialho A, Chakrabarty A, editors. Emerging cancer therapy: microbial approaches and biotechnological tools. Hoboken (NJ): John Wiley & Sons; 2010. p. 333-66.
- 41. Manderville RA. Synthesis, proton-affi nity and anti-cancer properties of the prodigiosin-group natural products. Curr Med Chem Anticancer Agents 2001;1:195-218. PMID: 12678767
- 42. Bernardes N, Seruca R, Chakrabarty AM, Fialho AM. Microbial-based therapy of cancer. Bioeng Bugs 2010;1:178-90. doi: 10.4161/bbug.1.3.10903
- 43. Chawrai SR, Williamson NR, Salmond GPC, Leeper FJ. Chemoenzymatic synthesis of prodigiosin analoguesexploring the substrate specifi city of PigC. Chem Commun 2008;16:1862-4. doi: 10.1039/B719353J
- 44. Cancerquest. Doxorubicin [displayed 9 June 2013]. Available at http://www.cancerquest.org/drugs/doxorubicin
- 45. Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, Campagnaro E, Brozo C, Braun T, Talpaz M, Kaminski MS. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009;27:5015-22. doi: 10.1200/ JCO.2008.19.5370
- 46. Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993;45:788-856. PMID: 7686469
- 47. The Scott Hamilton CARES Initiative. Mitoxantrone [displayed 9 June 2013]. Available at http://www.chemocare.com/bio/mitoxantrone.asp
- 48. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Hiroshi Kohno H, Nakajima Y, Komatsu H, Andoh T, Tsuruo T. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an invitro and in vivo human cancer cell line panel. Cancer Res 1999;59:4042-9. PMID: 10463605
- 49. David-Cordonnier MH, Hildebrand MP, Baldeyrou B, Lansiaux A, Keuser C, Benzschawel K, Lemster T, Pindur U. Design, synthesis and biological evaluation of new oligopyrrole carboxamides linked with tricyclic DNAintercalators as potential DNA ligands or topoisomerase inhibitors. Eur J Med Chem 2007;42:752-71. PMID: 17433851
- 50. Bhuyan BK, Newell KA, Crampton SL, Von Hoff DD. CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DMA synthesis, and cell survival. Cancer Res 1982;42:3532-7. PMID: 7105029
- 51. Wanga X, Chub N, Wanga N, Chao Liua Q, Jianga C, Wanga X, Ikejima T, Chenga M. Newly synthesized bis-benzimidazole derivatives exerting anti-tumor activity through induction of apoptosis and autophagy. Bioorg Med Chem Lett 2012;22:6297-300. doi: 10.1016/j.bmcl.2012.06.102
- 52. Hirota M, Fujiwara T, Mineshita S, Sugiyama H, Teraoka H. Distamycin A enhances the cytotoxicity of duocarmycin A and suppresses duocarmycin A-induced apoptosis in human lung carcinoma cells. Int J Biochem Cell Biol 2007;39:988-96. doi: 10.1016/j.biocel.2007.01.019
- 53. Bielawski K, Wolczynski S, Bielawska A. DNA-binding properties and cytotoxicity of extended aromatic bisamidines in breast cancer MCF-7 cells. Pol J Pharmacol 2001;53:143-7. PMID: 11787954
- 54. Yang YH, Cheng MS, Wang QH, Nie H, Liao N, Wang J, Chen H. Design, synthesis, and anti-tumor evaluation of novel symmetrical bis-benzimidazoles. Eur J Med Chem 2009;44:1808-12. doi: 10.1016/j.ejmech.2008.07.021
- 55. Chen AY, Yu C, Bodley A, Peng LF, Liu LF. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res 1993;53:1332-7. PMID: 8383008
- 56. Pilch DS, Xu Z, Sun Q, Lavoie EJ, Liu LF, Breslauer KJ. A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: A potential mechanism for topoisomerase I poisoning. Proc Natl Acad Sci USA 1997;94:13565-70.
- 57. Bailly C, Chessaro G, Carrasco C, Joubert A, Mann J, Wilson WD, Neidle S. Sequence-specifi c minor groove binding by bis-benzimidazoles: water molecules in ligand recognition. Nucleic Acids Res 2003;31:1514-24. PMID: 12595560
- 58. Vekshin N. Binding of Hoechst with nucleic acids using fl uorescence spectroscopy. J Biophys Chem 2011;2:443-7. doi: 10.4236/jbpc.2011.24052
- 59. Invitrogen. Hoechst Stains [displayed 9 June 2013]. Available at http://probes.invitrogen.com/media/pis/mp21486.pdf
- 60. Leitner F, Paillasson S, Ronot X, Demongeot J. Dynamic functional and structural analysis of living cells: new tools for vital staining of nuclear DNA and for characterisation of cell motion. Acta Biotheor 1995;43:299-317. PMID: 8919346
- 61. Chen AY, Yu C, Gatto B, Liu LF. DNA minor groove-binding ligands: A different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci USA 1993;90:8131-5. doi: 10.1073/pnas.90.17.8131
- 62. Baraldi PG, Cacciari B, Guiotto A, Romagnoli R, Zaid AN, Spalluto G. DNA minor-groove binders: results and design of new antitumor agents. Il Farmaco 1999;54:15-25. doi: 10.1016/S0014-827X(98)00102-5
- 63. Kamal A, Reddy PS, Reddy DR, Laxman E. DNA binding potential and cytotoxicity of newly designed pyrrolobenzodiazepine dimers linked through a piperazine side-armed-alkane spacer. Bioorg Med Chem 2006;14:385-94. PMID: 16185884
- 64. ClinicalTrails.gov. SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia [displayed 9 June 2013]. Available at http://clinicaltrials.gov/ct2/show/NCT00301769
- 65. Baron RM, Lopez-Guzman S, Riascos DF, Macias AA, Layne MD, Cheng G, Harris C, Chung SW, Reeves R, von Andrian UH, Perrella MA. Distamycin A inhibits HMGA1-binding to the P-selectin promoter and attenuates lung and liver inflammation during murine endotoxemia. PLoS One 2010;5:e10656. doi: 10.1371/journal.pone.0010656
- 66. Nelson SM, Ferguson LR, Denny WA. Non-covalent ligand/ DNA interactions: Minor groove binding agents. Mutat Res 2007;623:24-40. PMID: 17507044
- 67. Cortesi R, Romagnoli R, Drechsler M, Menegatti E, Zaid AN, Ravani L, Esposito E. Liposomes- and ethosomesassociated distamycins: as comparative study. J Liposome Res 2009;20:277-85. doi: 10.3109/08982100903443057
- 68. Cozzi P. A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers. Il Farmaco 2001;56:57-65. doi: 10.1016/S0014-827X(01)01009-6
- 69. Vialleta TBJ, Stewart D, Shepherdd F, Ayoubb J, Cormief Y, DiPietrof N, Stewardg W. Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Lung Cancer 1996;15:367-73. PMID: 8959681
- 70. Punt CJA, Humblet Y, Roca E, Dirix LJ, Wainstein R, Polli A, Corradino I. Tallimustine in advanced previously untreated colorectal cancer, a phase II study. Br J Cancer 1996;73:803-4. PMID: 8611384
- 71. Neidle S, Kelland LR, Trent JO, Simpson IJ, Boykin DW, Kumar A, Wilson WD. Cytotoxicity of bis(Phenylamidiniu m)furan alkyl derivatives in human tumour cell lines: realation to DNA minor groove binding. Bioorg Med Chem Lett 1997;7:1403-8. doi: 10.1016/S0960-894X(97)00229-1
- 72. Smith JA, Bifulco G, Case DA, Boger DL, Gomez-Paloma L, Chazin WJ. The Structural basis for in situ activation of DNA alkylation by duocarmycin. J Mol Biol 2000;300:1195-204. PMID: 10903864
- 73. Tietze LF, Schuster HJ, Schmuck K, Schuberth I, Alves F. Duocarmycin-based prodrugs for cancer prodrug monotherapy. Bioorg Med Chem 2008;16:6312-8. doi: 10.1016/j.bmc.2008.05.009 Mišković K, et al. ANTINEOPLASTIC DNA BINDING COMPOUNDS Arh Hig Rada Toksikol 2013;64:593-602